Home > Oncology > ELCC 2019 > Current Management of Early Stage NSCLC > Treatment options in early NSCLC

Treatment options in early NSCLC

Presented By
Dr Walter Weder, Dr Raffaele Califano
Conference
ELCC 2019
Trial
CALGB 9633
Both adjuvant and neo-adjuvant chemotherapy are standard-of-care for fit patients, at least for those with resected or resectable stage 2 or 3 non-small cell lung cancer (NSCLC). There is a strong rationale for perioperative immune checkpoint blockade and targeted therapies, such as ALK- and EGFR-directed tyrosine kinase inhibitors (TKIs). Should we use neoadjuvant chemotherapy, and not upfront surgery in combination with adjuvant treatment of early stage NSCLC? The answer is still not clear. A previous trial showed no statistically significant differences in disease-free survival (DFS) with the addition of preoperative or adjuvant chemotherapy to surgery [1]. In contrast, a recently published analysis of the National Cancer Database showed that both adjuvant and neoadjuvant chemotherapy result in better survival rates than surgery alone in patients with stage 2 or 3 lung cancer [2]. “The guidelines of the European Society of Thoracic Surgeons (ESTS...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on